BeStock  
Stocks › Biotechnology › DMRA

Damora Therapeutics DMRA

US equityMarket cap rank #2901Biotechnology
$23.22 −$1.08 (-4.44%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $23.22 0.00%
Open$23.81
Prev close$24.30
Day range$23.13 – $24.51
Volume643.4K
Market cap$1.44B
P/E (TTM)13.6
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$36.86M-1,068.0% YoY
Net profit-$31.99M-921.1% YoY
Diluted EPS-$0.40+83.1% YoY
Free cash flow-$17.23M-558.8% YoY
Operating cash flow-$17.23M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-6.7MDec '24$-2.5MMar '25$-3.4MJun '25$-3.1MSep '25$-200.7MDec '25$-27.8MMar '26$-31.2MJun '26$-32.0MSep '26

Diluted EPS by quarter

-5.23Dec '24-1.92Mar '25-2.60Jun '25-2.36Sep '252.90Dec '25-0.62Mar '26-0.39Jun '26-0.40Sep '26

Free cash flow by quarter

$-4.9MDec '24$-2.4MMar '25$-2.2MJun '25$-2.6MSep '25$566.0KDec '25$-20.6MMar '26$-21.9MJun '26$-17.2MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-156.6%
Return on assets-107.4%
Return on invested capital-160.1%
Current ratio14.80
Liabilities / assets6.9%
Cash & investments$528.48M
Total debt$946,000.00
Net cash (debt)$527.53M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $36.86M $34.99M $30.81M $210.87M $201.70M
Selling and Admin Expenses $11.39M $9.45M $7.03M $9.69M $4.07M
-General & Admin Expense $11.39M $9.45M $7.03M $9.69M $4.07M
Research & Development $25.48M $25.54M $23.78M $201.19M $197.63M
Operating Profit -$36.86M -$34.99M -$30.81M -$210.87M -$201.70M
Net Non-Operating Interest Income (Expense) $4.16M $4.06M $3.07M $1.17M $1.00M
Non-Operating Interest Income $4.16M $4.06M $3.07M $1.17M $1.00M
Other Income (Expense) $713,000.00 $16,000.00 – -$84,000.00 $3,000.00
Gain on Sale of Security -$37,000.00 $16,000.00 – -$84,000.00 $3,000.00
Special Income (Charges) $750,000.00 – – $0.00 $0.00
-Gain on Sale of Property/Plant/Equipment $750,000.00 – – – –
Pretax Profit -$31.99M -$30.92M -$27.74M -$209.79M -$200.69M
Tax $0.00 $255,000.00 $42,000.00 $50,000.00 $44,000.00
Net Profit -$31.99M -$31.17M -$27.78M -$209.84M -$200.74M
Profit from Continuing Operations -$31.99M -$31.17M -$27.78M -$209.84M -$200.74M
Net Income to Parent Company -$31.99M -$31.17M -$27.78M -$209.84M -$200.74M
Net Income to Common Stockholders -$31.99M -$31.17M -$27.78M -$209.84M -$200.74M
Basic EPS -$0.40 -$0.39 -$0.62 -$3.98 $2.90
Diluted EPS -$0.40 -$0.39 -$0.62 -$3.98 $2.90
-Less:Restructuring and Mergern & Acquisition – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $532.63M $543.64M $535.44M $260.53M $260.53M
Total Current Assets $531.32M $543.59M $535.41M $260.42M $260.42M
Cash and Cash Equivalents & Short-Term Investments $528.48M $540.52M $532.90M $257.62M $257.62M
-Cash and Cash Equivalents $349.66M $540.52M $532.90M $257.62M $257.62M
-Short Term Investments $178.82M – – – –
Receivables $838,000.00 $880,000.00 $894,000.00 $899,000.00 $899,000.00
-Taxes Receivable $838,000.00 $880,000.00 $894,000.00 $899,000.00 $899,000.00
Prepaid Assets $70,000.00 $243,000.00 $410,000.00 $577,000.00 $577,000.00
Current Deferred Assets $1.46M $655,000.00 $1.21M $1.20M $1.20M
Other Current Assets $469,000.00 $1.30M – $125,000.00 $125,000.00
Total Non-Current Assets $1.31M $48,000.00 $34,000.00 $104,000.00 $104,000.00
Net PPE $830,000.00 – – $104,000.00 $104,000.00
-Gross PPE $830,000.00 – – $176,000.00 $176,000.00
Other Non-Current Assets $480,000.00 $48,000.00 $34,000.00 – –
Total Liabilities $36.87M $27.58M $23.84M $20.15M $20.15M
Total Current Liabilities $35.89M $27.55M $23.81M $20.07M $20.07M
Payables $11.05M $9.14M $12.83M $17.67M $17.67M
-Accounts Payable $6.08M $3.48M $819,000.00 $444,000.00 $444,000.00
-Other Payable $4.96M $5.66M $12.01M $17.22M $17.22M
Current Accrued Expenses $9.58M $6.47M $3.71M $864,000.00 $864,000.00
Short-Term Debt and Capital Lease Obligation $153,000.00 – – $15,000.00 $15,000.00
-Current Capital Lease Obligation $153,000.00 – – $15,000.00 $15,000.00
Other Current Liabilities $12.44M $10.63M $6.31M $1.08M $1.08M
Total Non-Current Liabilities $974,000.00 $27,000.00 $27,000.00 $81,000.00 $81,000.00
Long Term Debt and Capital Lease Obligation $946,000.00 – – $53,000.00 $53,000.00
-Long Term Capital Lease Obligation $946,000.00 – – $53,000.00 $53,000.00
Other Non-Current Liabilities $28,000.00 $27,000.00 $27,000.00 $28,000.00 $28,000.00
Total Equity $495.76M $516.06M $511.60M $240.38M $240.38M
Stockholders' Equity $495.76M $516.06M $511.60M $240.38M $240.38M
Capital Stock $130.00M $130.00M $132.45M $416.25M $416.25M
-Common Stock $1,000.00 $1,000.00 $1,000.00 $0.00 $0.00
-Preferred Stock $130.00M $130.00M $132.45M $416.25M $416.25M
Additional Paid-In Capital $944.31M $931.65M $893.54M $310.69M $310.69M
Retained Earnings -$578.31M -$546.32M -$515.15M -$487.36M -$487.36M
Gains/Losses Not Affecting Retained Earnings -$233,000.00 $732,000.00 $754,000.00 $802,000.00 $802,000.00
-Accumulated Depreciation – – – -$72,000.00 -$72,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$17.23M -$21.87M -$20.60M -$6.73M $566,000.00
Net cash flow from continuing operations -$17.23M -$21.87M -$20.60M -$6.73M $566,000.00
Net Income from Continuing Operations -$31.99M -$31.17M -$27.78M -$209.84M -$200.74M
Depreciation & Depletion & Amortization $264,000.00 $11,000.00 $68,000.00 $34,000.00 $7,000.00
Change in Working Capital $8.00M $3.15M $3.98M $18.36M $17.14M
-Change in Prepaid Assets $234,000.00 -$564,000.00 $290,000.00 -$138,000.00 -$620,000.00
-Change in Payables and Accrued Expense $5.86M -$790,000.00 -$1.24M $18.37M $16.95M
-Change in Other Current Assets -$438,000.00 -$23,000.00 $0.00 $166,000.00 $837,000.00
-Change in Other Current Liabilities $9,000.00 -$14,000.00 -$54,000.00 -$35,000.00 -$26,000.00
-Change In Other Working Capital $2.34M $4.54M $4.98M – –
Financing Cash Flow $5.12M $29.51M $295.92M $266.84M $266.84M
Net Cash Flow from Continuing Financing Activities $5.12M $29.51M $295.92M $266.84M $266.84M
Net Common Stock Issuance $5.29M $50.72M $295.50M – –
Proceeds from Stock Option Exercised $53,000.00 $226,000.00 $424,000.00 $33,000.00 $33,000.00
Net Other Financing Charges -$226,000.00 – – – –
Ending Cash Balance $349.66M $540.52M $532.90M $257.62M $257.62M
Net Change in Cash -$190.87M $7.64M $275.32M $242.74M $250.04M
Beginning Cash Balance $540.52M $532.90M $257.62M $14.18M $7.61M
Effect of Exchange Rate Changes $9,000.00 -$22,000.00 -$48,000.00 $705,000.00 -$18,000.00
Free Cash Flow -$17.23M -$21.87M -$20.60M -$6.73M $566,000.00
Gain/Loss from Continuing Operations – – – $9.36M –
Other Non-Cash Items – – – $174.36M $174.31M
Net cash flow from investing – – – -$17.37M -$17.37M
Net Cash Flow from Continuing Investing Activities – – – -$17.37M -$17.37M
Net Business Purchase and Sale – – – -$17.37M –
Net Investment Purchase and Sale – – – $0.00 $0.00
Net Preferred Stock Issuance – – – $266.81M –

Discussion

No comments yet — be the first to weigh in on DMRA.

Sign in to join the discussion.

Scroll to Top